NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Wednesday, November, 6th. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.49. The firm earned $168 million during the quarter, compared to analysts' expectations of $152.47 million. The company's revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.03) EPS. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

12 equities research analysts have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $75.82 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

Headlines about IONS stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 31st total of 7,700,000 shares. Based on an average trading volume of 983,700 shares, the days-to-cover ratio is presently 8.6 days. Currently, 6.6% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), BlackRock (BLK), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), First Trust Advisors LP (0.71%) and Sumitomo Mitsui Trust Holdings Inc. (0.69%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE, Rafferty Asset Management LLC and Goldman Sachs Group Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., Sumitomo Mitsui Trust Holdings Inc. and Amia Capital LLP. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $60.13.